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Background:  Pain on propofol injection is a well-known adverse effect.  We evaluated the clinical factors that affect 
the pain on injection of propofol to develop a strategy to prevent or reduce pain. 
Methods:  We conducted a prospective, observational study of 207 adult patients (ASA I-II), and the patients were 
classified according to gender, age, the body mass index (BMI), the IV site and the side of the IV site.  During the 10 
seconds after propofol injection, pain intensity was measured on an 11-point numerical rating scale (0 = no pain and 
10 = worst possible pain).  Pain in excess of 3 on the numerical scale was regarded as moderate to severe pain.
Results:  The subgroups of gender (female: 55.6% vs. male: 25.0%; P < 0.01) and the IV site (dorsum of hand: 61.2% 
vs. wrist: 40.0% vs. antecubital fossa: 22.5%; P < 0.01) had significantly different frequencies for the incidence of pain 
on injection on the univariate and multivariate analyses.  For the subgroup of females, the incidence of pain was 
statistically different according to the age group (20-40 yr: 71.0% vs. 41-60: 54.8% vs. 61-80: 38.5%; P = 0.014).
Conclusions:  Our results showed that the younger age patients, the patients with a peripheral IV site and female 
patients are more sensitive to pain on the injection of propofol.  (Korean J Anesthesiol 2010; 58: 239-243)
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Introduction 
    Propofol is a popular intravenous (IV) anesthetic drug, used 
for induction and maintenance during general anesthesia owing 
to its rapid onset and short duration. However, the incidence 
of pain following propofol injection is seen in approximately 
70% of patients, in the absence of other pretreatments [1-3]. 
The nature of pain was described as extremely sharp, aching 
or burning. It has been ranked as the seventh most important 
drawback in current practice of clinical anesthesia by American 
anesthesiologists [4]. The mechanism by which propofol 
induces pain on injection has remained unclear, but many 
factors that affect pain on injection are evaluated. Not only the 
intrinsic drug property (e.g. emulsion composition, pH of the 
formulation, temperature, injection volume and osmolarity) 
,but the injection procedure itself could contribute to injection 
pain [5-7], which includes the speed of pushing the medication 
during injection, propofol concentration in the aqueous 
phase, speed of IV carrier fluid, use of local anesthetics, and 
the buffering effect of blood [6,8,9]. In addition to this, many 240 www.ekja.org
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pretreatment agents have also been evaluated for prevention 
or reduction of the pain that accompanies propofol injection. 
There is a need to evaluate the clinical factors that affect the 
pain on propofol injection in each patient. However, till date, 
there is relatively very little published data on the clinical factors 
that affect the injection pain of propofol without pretreatment. 
Thus, we evaluated the clinical factors affecting the incidence 
of pain on propofol injection in patients scheduled for elective 
surgery. 
Materials and Methods
    The study was performed in 207 patients (ASA physical 
status I-II, aged 20-80 yr) undergoing elective surgery after 
receiving study approval by institutional review board (IRB) 
and informed consent from patients. Patients having problems 
in communication or psychological disorders, patients on 
analgesics or sedative were excluded from this study s. The 
body mass index (BMI) was calculated after measuring height 
and body weight of patients and was classified according to the 
cut-off points for Asian population as underweight (less than 
18.5 kg/m
2); normal weight (18.5-23.9 kg/m
2); overweight 
(23.0-27.49 kg/m
2); and obese (27.5 kg/m
2 or higher)[10]. No 
patients had received premedication before their arrival in the 
operating room or received analgesics within 24 hours before 
surgery. An 18-gauge catheter was inserted at approximately 
120 minutes before induction of anesthesia for venous access 
and was classified depending on the insertion site as dorsum 
of the hand, wrist or antecubital fossa, and the side of IV site as 
patient’s dominant hand side or not. All drugs were prepared 
and stored at room temperature and used within 30 minutes of 
preparation. The induction dose of propofol was 2 mg/kg. On 
arrival in the operating room, patients were routinely monitored 
and received 0.5 mg/kg of propofol (1.0%/12 ml ampoule, 
Pofol
Ⓡ, Jeil Pharm) by 0.3 ml/sec through the IV cannula with 
closed infusion line. During first 10 seconds after receiving 
first dose of propofol patients were asked standard questions 
regarding their comfort or pain during the injection. Pain 
intensity was measured on an 11-point pain intensity numerical 
rating scale (PI-NRS), where 0 = no pain and 10 = worst pain 
possible. Based on previously published data, pain of moderate 
to severe intensity was assessed if the PI-NRS score was found to 
be more than 3 [11]. Induction of anesthesia was continued with 
the 1.5 mg/kg of propofol. After patients lost consciousness, 
rocuronium 0.6 mg/kg was given to facilitate muscle relaxation 
and tracheal intubation, and anesthesia was maintained with 
sevoflurane 1.0% to 3.0% and nitrous oxide 50% in oxygen with 
controlled ventilation. Fentanyl was administered only after 
induction of anesthesia. Within 24 hours after operation, a 
researcher blinded to this study checked the injection site for 
pain, edema, wheal, flare response or any other adverse effect. 
 All statistical analyses were performed using SPSS software 
(version 12.0, SPSS Inc., IL, USA). Values are expressed as 
mean ± standard deviation (SD). Univariate statistical analysis 
was carried out using Student t-test and Chi-Square test to 
compare demographic data and incidence of propofol injection 
pain. Multivariate analysis for factors affecting injection pain 
performed stepwise logistic regression. Independent factors 
that had statistical significance or were close to this figure after 
univariate analysis were selected for the multivariate analysis. 
All tests were 2-sided and a value of P < 0.05 was considered 
statistically significant. 
Results 
    The results of pain on propofol injection were based on data 
derived from study on a total of 207 patients. Demographic 
data of patients were shown in Table 1. The incidence of pain 
was estimated from the ratio of patients experiencing pain on 
injection (PI-NRS > 3) to all patients in each group. Table 2 displays 
incidence of pain on injection, univariate and multivariate 
analyses of factors affecting the incidence of pain on injection. 
It was observed that female gender and dorsum of hand in IV 
site had a significantly greater frequency of pain on injection 
on the univariate analysis. Side of IV site (dominant hand side 
or not), BMI and age did not correlate significantly with the 
incidence of pain on injection. The factors that were associated 
independently with the incidence of pain on injection were 
gender and IV site according to the multivariate analysis (logistic 
regression model). Table 3 contains the distribution of patients 
by independent factors. The distribution of subgroups in each 
gender group were not statistically different with respect to age 
and IV site (male: P = 0.42; female: P = 0.78). The peripheral 
IV site groups showed higher incidence of pain on injection 
in both gender groups (P < 0.01). In a subgroups of female 
patients, the incidence of pain was significantly different by 
age group (20-40 yr: 71.0% vs. 41-60: 54.8% vs. 61-80: 38.5%; 
P = 0.014). The higher incidence of pain on injection was seen 
in younger groups. In the subgroups of males, the incidence of 
pain was however, not different among the different age groups 
(20-40 yr: 23.4% vs. 41-60: 27.8% vs. 61-80: 24.0%; P = 0.89).
Table 1. Patients Demographics (n = 207)
Age (years)
Gender (Male : Female)
Height (cm)
Weight (kg)
46.9 ± 16.4
108 : 99  
163.3 ± 9.6
64.2 ± 10.6
Values are expressed as mean ± standard deviation, except gender.241 www.ekja.org
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Discussion
    Propofol has been widely used for induction and maintenance 
of anesthesia, but pain that accompanies propofol injection can 
be very distressing to the patients [6]. Until now, the mechanism 
of pain following propofol injection has been unclear. Propofol 
belongs to the group of phenols that can directly irritate 
the skin, mucous membrane and venous intima and could 
immediately stimulate nociceptors and free nerve endings 
[12]. The concentration of aqueous free propofol is related to 
injection pain. By its indirect action on the endothelium, it was 
suggested that propofol activates the kallikrein-kinin system 
and releases bradykinin, thereby producing venous dilation 
and hyperpermeability, which increases the contact between 
aqueous phase of propofol and free nerve endings, results in 
delayed pain within half a minute [8,13]. Recently several studies 
have suggested that propofol had no effect on the concentration 
of bradykinin in plasma, compared with saline control group [14,15]. 
    Strategies to reduce the pain on injection includes addition 
of lidocaine, cooling or diluting the propofol solution, and pre-
treatment with lidocaine, ephedrine, ondansetron, metoclo-
pramide, nafamostat mesilate, opioids, thiopental, or keta-
mine [1,2,12,16-20]. The most frequently used analgesic method 
Table 2. Univariate and Multivariate Analysis of Factors Affecting the Incidence of Pain on Propofol Injection
Factors (n)
Univariate analysis Multivariate analysis
Incidence of pain P value Odds ratio (95% C.I.) P value
Gender 
    Male (108) 
    Female (99) 
Age (yr)
    20-40 (78)
    41-60 (78)
    61-80 (51) 
IV site
    Antecubital fossa (80)
    Wrist (65)
    Dorsum of hand (62)
BMI (cm/kg
2) 
    < 18.5 (4)
    18.5-22.9 (80)
    23.0-27.49 (88)
    >27.5 (35)
Side of IV site
    Dominant hand (94)
    Non-dominant hand (113)
25.0%
55.6%
42.3%
42.3%
31.4%
22.5%
40.0%
61.2%
50.0%
40.0%
38.6%
40.0%
40.4%
38.9%
< 0.01
0.39
< 0.01
0.97
0.83
1.0 (reference)
3.90 (2.06-7.38)
2.09 (0.91-4.80)
1.44 (0.63-3.27)
1.0 (reference)
1.0 (reference)
2.02 (0.95-4.31)
5.31 (2.44-11.59)
Not analyzed
Not analyzed
< 0.01
0.21
< 0.01
Table 3. Incidence of Pain* on Injection and the Distribution of Patients
†
IV site
 Age (yrs)
20-40 41-60 61-80
Male (n=108)
‡    
    Dorsum of hand
    Wrist
    Antecubital fossa
Female (n=99) 
‡,§
    Dorsum of hand 
    Wrist
    Antecubital fossa
40.0%
10 (9.3%)
29.4%
17 (15.7%)
10.0%
20 (18.5%)
80.0%
10 (10.1%)
70.0%
10 (10.1%)
63.6%
11 (11.1%)
54.5%
11 (10.2%)
20.0%
10 (9.3%)
13.3%
15 (13.9%)
70.6%
17 (17.2%)
50.0%
14 (14.1%)
36.4%
11 (11.1%)
42.8%
7 (6.5%)
25.0%
4 (3.7%)
14.3%
14 (13.0%)
71.4%
7 (7.1%)
40.0%
10 (10.1%)
11.1%
9 (9.1%) 
*%, patients experiencing pain on injection (pain intensity numerical 
rating scale >3), 
†Number (%) among the same gender patients. 
‡P < 0.01 intergroup comparison among IV site subgroups, 
§P = 0.014 
intergroup comparison among age groups.242 www.ekja.org
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is IV lidocaine (0.5 mg/kg) on the antecubital fossa, given as a 
Bier’s block, 30 to 120 seconds before the injection of propofol [1]. 
    The incidence and the severity of pain following propofol 
injection is directly related to site of injection and smaller 
size of the vessels [8]. In children, younger the age, higher is 
the incidence and severity of pain on propofol injection [21] 
attributable to the smaller size of vein in younger children. 
The present study also pointed out that incidence of pain on 
propofol injection was different between the different IV sites, 
and the highest frequency was observed in dorsum of hand. 
This finding is consistent with the previously published studies 
[9,13,22]. The injection procedure itself affects the incidence 
and severity of pain on injection, the pain can be reduced by 
the injection of propofol into the vein of antecubital fossa [8, 
9]. However, it is not feasible to recommend all anesthetists 
to choose the antecubital fossa vein to avoid propofol 
injection pain as the IV site in antecubital fossa is relatively 
uncomfortable to patients and has a tendency to occlude. 
    In a study conducted to examine the influence of aging on 
lidocaine requirements for propofol-induced pain, the elderly 
patients needed relatively small dose of lidocaine to reduce the 
pain compared with the young patients [23]. In our study, the 
significant differences and the downward tendency with age 
were observed in the pain incidence of female patients. The 
exact reason for this difference is not known, but it could be 
because of the aging influence on pain thresholds [3,24]. 
    Till date, the relationship between gender and propofol 
injection pain needs to be established. It has been accepted 
that there is no gender difference in the incidence of pain on 
propofol injection without any specific references or targeted 
research work [3,23]. Therefore, this study evaluated the 
differences in pain incidence between male and female. Gender 
is the baseline data in any research for selecting or distributing 
the patients, and this gender related bias is an important 
demographic parameter that is observed during conduct of any 
clinical study. The present study showed that male patients had 
lower incidence of injection pain than female patients. Propofol 
is distributed in two phases with an outer aqueous phase and 
an inner lipid phase in the propofol emulsion preparation. Only 
the outer aqueous phase comes into contact with intima of the 
vein, so the concentration of an irritating agent in the aqueous 
phase is considered to the main cause of pain due to propofol 
injection [6,25]. The proposed reason of gender difference in 
propofol-induced pain is firstly due to the mechanical effect 
that male has larger sized veins than female while another factor 
suggested is the difference of pain sensitivity observed between 
the gender and this emphasizes the necessity of specifying 
the patients’ gender while investigating propofol-associated 
withdrawal. Clinically, it is a fact that female experiences 
greater pain intensity, with or without related distress, and 
shows heightened sensitivity to experimentally induced pain 
compared to that of males [26-30]. Further analysis is needed 
to evaluate the relationship between gender and pain-related 
variables. Continued research at the genetic and receptor levels 
may support the need to develop gender-specific drug therapies 
[29].
    Our finding must be considered within the context of the study 
limitation. First, the patients were not assigned to subgroups 
by randomization. Second, the sample size for subgroup 
was relatively small. Third, the comparison for pain intensity 
with pretreatment was not evaluated. Further studies should 
consider these limitations and evaluate other possible factors 
that could affect the injection pain, and develop strategies 
for preventing or reducing the pain on injection of propofol, 
considering the factors such as drug property, kinds of pretreat-
ment and procedure and associated clinical factors. 
    Propofol induced pain is a common problem during induction 
of general anesthesia. Our results showed that the younger 
age patients, the patients with a peripheral IV site and female 
patients are more sensitive to pain following IV injection of 
propofol. Therefore clinicians need to have strategies to reduce 
or prevent the pain for patients, who have factors affecting the 
pain on injection of propofol.
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